Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188
Authors:
- Mary A VoglerMVMary A Vogler
- Kristine PattersonKPKristine Patterson
- Lori KamemotoLKLori Kamemoto
- Jeong-Gun ParkJPJeong-Gun Park
- Heather WattsHWHeather Watts
- Francesca AweekaFAFrancesca Aweeka
- Karin L KlingmanKKKarin L Klingman
- Susan E CohnSCSusan E Cohn
- 1 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 55 (4) , 473-482
Abstract
Background: Pharmacokinetic (PK) interactions between lopinavir/ritonavir (LPV/r) and transdermally delivered ethinyl estradiol (EE) and norelgestromin (NGMN) are unknown. Methods: Using a standard noncompartmental PK analysis, we compared EE area under the time-concentration curve (AUC) and NGMN AUC during transdermal contraceptive patch administration in HIV-1-infected women on stable LPV/r to a control group of women not on highly active antiretroviral therapy (HAART). In addition, EE AUC after a single dose of a combination oral contraceptive pill including EE and norethindrone was measured before patch placement and was compared with patch EE AUC in both groups. Contraceptive effects on LPV/r PKs were estimated by measuring LPV/r AUC at baseline and during week 3 of patch administration. Results: Eight women on LPV/r, and 24 women in the control group were enrolled. Patch EE median AUC0−168 h was 45% lower at 6010.36 pg·h·mL−1 in those on LPV/r versus 10911.42 pg·h·mL−1 in those on no HAART (P = 0.064). Pill EE median AUC0−48 hours was similarly 55% lower at 344.67 pg·h·mL−1 in those on LPV/r versus 765.38 pg·h·mL−1 in those on no HAART (P = 0.003). Patch NGMN AUC0−168 h however, was 138.39 ng·h·mL−1, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL−1 (P = 0.036). After 3 weeks on the patch, LPV AUC0−8 h decreased by 19%, (P = 0.156). Conclusions: Although PKs of contraceptive EE and NGMN are significantly altered with LPV/r, the contraceptive efficacy of the patch is likely to be maintained. Larger studies are indicated to fully assess contraceptive efficacy versus risks of the transdermal contraceptive patch when co-administered with protease inhibitors.Keywords
This publication has 26 references indexed in Scilit:
- Pregnancy, Contraceptive Use, and HIV Acquisition in HPTN 039: Relevance for HIV Prevention Trials Among African WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception StudyBMJ, 2010
- Hormonal contraception and risk of venous thromboembolism: national follow-up studyBMJ, 2009
- Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093Contraception, 2008
- Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptivesThe European Journal of Contraception & Reproductive Health Care, 2008
- Contraception and fertility plans in a cohort of HIV-positive women in careContraception, 2007
- Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System UsersObstetrics & Gynecology, 2007
- An Update on Therapeutic Drug Monitoring for Antiretroviral DrugsTherapeutic Drug Monitoring, 2006
- Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteersBritish Journal of Clinical Pharmacology, 1998